- Home
- AMRN vs EPIX Comparison
AMRN vs EPIX Comparison
Compare AMRN & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- EPIX
- Stock Information
- Founded
- AMRN 1989
- EPIX 2009
- Country
- AMRN Ireland
- EPIX Canada
- Employees
- AMRN N/A
- EPIX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- EPIX Health Care
- Exchange
- AMRN Nasdaq
- EPIX Nasdaq
- Market Cap
- AMRN 236.4M
- EPIX 209.4M
- IPO Year
- AMRN 1993
- EPIX N/A
- Fundamental
- Price
- AMRN $0.50
- EPIX $1.72
- Analyst Decision
- AMRN Hold
- EPIX Hold
- Analyst Count
- AMRN 2
- EPIX 4
- Target Price
- AMRN N/A
- EPIX $9.50
- AVG Volume (30 Days)
- AMRN 1.2M
- EPIX 2.4M
- Earning Date
- AMRN 10-30-2024
- EPIX 12-10-2024
- Dividend Yield
- AMRN N/A
- EPIX N/A
- EPS Growth
- AMRN N/A
- EPIX N/A
- EPS
- AMRN N/A
- EPIX N/A
- Revenue
- AMRN $241,021,000.00
- EPIX N/A
- Revenue This Year
- AMRN N/A
- EPIX N/A
- Revenue Next Year
- AMRN N/A
- EPIX N/A
- P/E Ratio
- AMRN N/A
- EPIX N/A
- Revenue Growth
- AMRN N/A
- EPIX N/A
- 52 Week Low
- AMRN $0.50
- EPIX $1.40
- 52 Week High
- AMRN $1.37
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- AMRN 32.91
- EPIX 23.15
- Support Level
- AMRN $0.54
- EPIX $1.75
- Resistance Level
- AMRN $0.58
- EPIX $1.89
- Average True Range (ATR)
- AMRN 0.04
- EPIX 0.19
- MACD
- AMRN -0.01
- EPIX -0.10
- Stochastic Oscillator
- AMRN 2.97
- EPIX 7.36
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.